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BRIEF COMMUNICATION OPEN
Migrating the SNP array-based homologous recombination
deﬁciency measures to next generation sequencing data of
breast cancer
Zsoﬁa Sztupinszki1, Miklos Diossy1, Marcin Krzystanek1, Lilla Reiniger2,3, István Csabai4, Francesco Favero 5, Nicolai J. Birkbak6,7,
Aron C. Eklund 1, Ali Syed8 and Zoltan Szallasi1,3,9,10
The ﬁrst genomic scar-based homologous recombination deﬁciency (HRD) measures were produced using SNP arrays. As array-
based technology has been largely replaced by next generation sequencing approaches, it has become important to develop
algorithms that derive the same type of genomic scar scores from next generation sequencing (whole exome “WXS”, whole
genome “WGS”) data. In order to perform this analysis, we introduce here the scarHRD R package and show that using this method
the SNP array-based and next generation sequencing-based derivation of HRD scores show good correlation (Pearson correlation
between 0.73 and 0.87 depending on the actual HRD measure) and that the NGS-based HRD scores distinguish similarly well
between BRCA mutant and BRCA wild-type cases in a cohort of triple-negative breast cancer patients of the TCGA data set.
npj Breast Cancer  (2018) 4:16 ; doi:10.1038/s41523-018-0066-6
INTRODUCTION
Reliable quantiﬁcation of homologous recombination deﬁciency
of human tumor biopsies, especially in the case of ovarian and
breast cancer, is expected to identify patients that are particularly
sensitive to platinum or PARP inhibitor-based therapy.1 Before the
widespread introduction of next generation sequencing (NGS) to
characterize tumor biopsies, SNP arrays were used to identify
large-scale genomic aberrations associated with homologous
recombination deﬁciency, often induced by the loss of BRCA1 or
BRCA2 function. Three such measures were identiﬁed: telomeric
allelic imbalance (HRD-TAI score),2 loss of heterozygosity proﬁles
(HRD-LOH score),3 and large-scale state transitions (HRD-LST
score).4 These three measures have also been combined into a
single summary measure of HR deﬁciency.5 The HRD-LOH score
has also become an integral part of a recently published, whole-
genome sequencing-based measure of homologous recombina-
tion deﬁciency, HRDetect.6 These measures, along with functional
assays,7 showed promise to identify HR-deﬁcient cases and thus
predict response to platinum or PARP inhibitor therapy.2,8,9 Since
NGS has become the main genomic characterization method of
cancer biopsies, it has become essential to migrate the SNP array-
based methodology to NGS-based platforms.
TCGA breast cancer biopsies have been both SNP array proﬁled
and subjected to NGS allowing a direct comparison.8
RESULTS AND DISCUSSION
We found good correlation between the SNP array-based and
NGS-based HRD scores (Fig. 1). When comparing the results of the
scarHRD R package to SNP array-based measurements, we found
the following Pearson correlation coefﬁcients: number of telo-
meric allelic imbalances (NtAI): r= 0.84 (R2= 0.70, adjusted R2=
0.70, p < 2.2e–16), large-scale transition (LST) r= 0.79 (R2= 0.62,
adjusted R2= 0.62, p < 2.2e–16) loss of heterozygosity (HRD−LOH)
r= 0.73 (R2= 0.53, adjusted R2= 0.52, p < 2.2e–16). These three
measures are often combined for diagnostic purposes5 and in
HRDetect.6 Therefore, we also compared the sum of the three
scores across the two platforms (HRD sum): r= 0.87 (R2= 0.75,
adjusted R2= 0.75, p < 2.2e–16) (Fig. 1). The artiﬁcial reduction of
coverage to 30× did not affect this correlation (Supplementary
Material, Figure S7-S8). The BRCA1/2-mutated samples showed
signiﬁcantly higher NGS-based HRD-sum values (Fig. 2, Supple-
mentary Figure S6). The predictive value of HRD-sum, measured as
AUC value of the corresponding ROC curve, was 80.8%
(Supplementary Figure S2).
There was no signiﬁcant difference in SNP versus WXS-based
estimation of tAI, LST, and HRD-sum, but the number of LOH
events were signiﬁcantly lower in the WXS-based estimation (p=
0.012, Kolmogorov–Smirnov test). This could be attributed to
differences in segmentation algorithm (the more segmented the
WXS data is the lower number of LOHs that are called) or to low
sample quality, coverage. However, when comparing the ROC
curves for BRCA1/2 status of the SNP-based and WXS-based HRD-
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score, there was no signiﬁcant difference between the SNP array-
based and NGS-based methods. (Supplementary Figure S3).
According to our expectations and previous results the BRCA1/
2-deﬁcient cases showed higher values for each of the four scores
(Supplementary Figure S4-S5).
The sum of the three HRD scores showed good correlation
across the two platforms. Thus in more advanced NGS-based HR
deﬁciency measures such as HRDetect, the SNP array-based step
could be replaced by an NGS-based estimate of the HR deﬁciency
scores.
Brief description of the methods
Based on receptor status determined by immunohistochemistry,
139 paired tumor and normal samples of the TCGA breast cancer
cohort could be classiﬁed as triple-negative breast cancer. From
these patients 95 had Affymetrix SNP 6.0 array-based HRD
estimates (LOH, TAI, LST), previously published by our group.10
In this publication we present the scarHRD R package (https://
github.com/sztup/scarHRD) which estimates the level of the three
HR deﬁciency measures using NGS data.
A sample’s LOH score is the total number of LOH regions across
the entire genome that are larger than 15 Mb but do not cover
whole chromosomes. In the original publication this 15 Mb lower
limit for LOH was determined by comparing SNP array proﬁles
between BRCA mutant and BRCA wild-type cases.3 We performed
a similar analysis using NGS data and found that the original
15 Mb cutoff performed best in this case as well (Supplementary
Figure S1).
The LST is deﬁned as a chromosomal break between adjacent
regions of at least 10 Mb, with a distance between them not larger
than 3 Mb.
Fig. 1 Correlation between Affymetrix SNP 6.0 array-based and whole exome sequencing-based measurements of homologous
recombination deﬁciency (telomeric allelic imbalance, loss of heterozygosity, large-scale transitions, and the sum of these estimates)
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The number of telomeric allelic imbalances is the number of AIs
(the unequal contribution of parental allele sequences with or
without changes in the overall copy number of the region) that
extend to the telomeric end of a chromosome.
Allele-speciﬁc copy number estimation is a crucial part of
estimating HR deﬁciency. As previously shown, allele-speciﬁc copy
number estimation from NGS data performed using the Sequenza
R package show high agreement with SNP array-based copy
number proﬁles.11 The scarHRD package is, therefore, able to use
Sequenza preprocessed ﬁles as well as other allele-speciﬁc
segmentation ﬁles in the same format.
As it has been previously shown that in ovarian cancer the sum
of the genomic scar scores is elevated in BRCA-deﬁcient cancers,5
an additional aim of our study was to compare the unweighted
numeric sum of LOH, tAI, and LST, called here HRD-sum, to the
BRCA1/2 status of the patients. A sample was classiﬁed as BRCA-
deﬁcient if (1) there was a deep deletion of BRCA1/2, (2) a
germline and a somatic mutation in BRCA1/2 with LOH, or (3) if
LOH had co-occurred with promoter methylation in one of the
BRCA1/2 genes. The somatic mutation status (mutations with likely
pathogenic function) and methylation data was acquired from the
TCGA data portal. The germline mutation status was determined
using HaplotypeCaller, and was annotated with Intervar,12 likely
pathogenic mutations and frameshift insertion/deletion with
unknown signiﬁcance were used in our analysis. LOH was
determined using Sequenza’s allele-speciﬁc segmentation results
(Supplementary Table S1).
Data availability
The data sets generated during the current study are available
from the corresponding author on reasonable request.
Code availability
The code/algorithm for performing the experiments is available
for download at https://github.com/sztup/scarHRD.
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Fig. 2 Distribution of HRD-sum values in BRCA1/2 deﬁcient and in BRCA1/2 intact triple-negative breast cancer samples from TCGA. HRD-sum
values were determined with the scarHRD R package
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